BJ Bioscience   Report issue

For profit Phase 1
Founded: Hangzhou China (2018)

Organization Overview

First Clinical Trial
2019
NCT04294576
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

BJ Bioscience | BJ Bioscience, Inc.

Active Ingredients

Drugs in Phase 1 Trials (3)

bj-001 (1 trial)

bj-005 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3